IMforte: A new starting point and new challenges.

IF 11.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-08-08 DOI:10.1016/j.medj.2025.100777

Ying Cheng, Shuang Zhang

引用次数: 0

Abstract

The IMforte study¹ demonstrated that maintenance treatment with atezolizumab plus lurbinectedin significantly improved progression-free survival and overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC). This phase 3 study is the first to report a positive result in first-line maintenance therapy for ES-SCLC, representing another milestone that is likely to establish a new standard of care for this condition.

查看原文本刊更多论文

新的起点，新的挑战。

IMforte研究1表明，用atezolizumab和lurbinectedin维持治疗可显著改善广泛期小细胞肺癌（ES-SCLC）患者的无进展生存期和总生存期。这项3期研究首次报道了ES-SCLC一线维持治疗的阳性结果，代表了另一个里程碑，可能为这种疾病建立新的护理标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.